Krka ESG Rating

On 24 November 2023, Krka scored 50 (out of 100) in the 2023 S&P Global Corporate Sustainability Assessment. As of 24 November 2023, Krka’s S&P Global* CSA Score ranked among top 10% companies in the pharmaceutical industry in the S&P Global Corporate Sustainability Assessment.

The received independent score affirms the outlined direction of the Krka Group’s sustainable management practices and ESG governance, where we prioritize our social responsibility and care for the health and well-being of patients.

We provide them with access to high-quality, safe, and effective medicines produced in accordance with the highest standards of good manufacturing practice. In this process, we place significant emphasis on environmental protection and reducing our environmental impact. In the governance of the Krka Group, we adhere to the highest standards of business ethics, integrity, and transparent operations.

The received score serves as both an encouragement and a commitment to further improve the sustainability practices in the Krka Group.

*Standard & Poor’s (S&P) is a global leading index provider and data source of independent credit ratings and CSA/ESG scores.